Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease

Low-density lipoprotein cholesterol (LDL-C) is associated with heightened risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in peripheral artery disease (PAD). Lipid-lowering therapies (LLT) that reduce LDL-C decrease this risk. The authors examined LLT use and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2021-06, Vol.77 (24), p.3016-3027
Main Authors: Hess, Connie N., Cannon, Christopher P., Beckman, Joshua A., Goodney, Philip P., Patel, Manesh R., Hiatt, William R., Mues, Katherine E., Orroth, Kate K., Shannon, Erin, Bonaca, Marc P.
Format: Article
Language:English
Subjects:
lipid management
outcomes
peripheral artery disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Low-density lipoprotein cholesterol (LDL-C) is associated with heightened risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in peripheral artery disease (PAD). Lipid-lowering therapies (LLT) that reduce LDL-C decrease this risk. The authors examined LLT use and actual achieved LDL-C in PAD. PAD patients in MarketScan from 2014 to 2018 were identified. Outcomes included LLT use, defined as high-intensity (HI) (high-intensity statin, statin plus ezetimibe, or PCSK9 inhibitor), low-intensity (any other lipid regimen), or no therapy, and follow-up LDL-C. Factors associated with LDL-C
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2021.04.060